| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10637-011-9648-Y |
| P698 | PubMed publication ID | 21350803 |
| P50 | author | Keitaro Matsuo | Q30506416 |
| P2093 | author name string | Kohei Shitara | |
| Takashi Ura | |||
| Kei Muro | |||
| Daisuke Takahari | |||
| Tomoya Yokota | |||
| Junko Ikeda | |||
| P2860 | cites work | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 |
| Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints | Q27860640 | ||
| Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world | Q29614969 | ||
| Capecitabine and oxaliplatin for advanced esophagogastric cancer. | Q33313072 | ||
| Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer | Q33341957 | ||
| Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction | Q33380002 | ||
| A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin | Q33421327 | ||
| Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer | Q33488159 | ||
| Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial | Q33658659 | ||
| Detecting an overall survival benefit that is derived from progression-free survival | Q34063143 | ||
| Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 | ||
| S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial | Q34588472 | ||
| Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. | Q34603290 | ||
| A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction | Q34609932 | ||
| Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial | Q34616772 | ||
| Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer | Q36309823 | ||
| Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer | Q36616011 | ||
| A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer | Q36858273 | ||
| Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. | Q36944493 | ||
| Diverse eastern and Western approaches to the management of gastric cancer. | Q37141671 | ||
| Randomized, multicenter, phase III trial of heptaplatin 1-hour infusion and 5-fluorouracil combination chemotherapy comparing with cisplatin and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer | Q37234210 | ||
| Time to progression as a surrogate marker for overall survival in patients with advanced non-small cell lung cancer | Q37384651 | ||
| Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature | Q37630084 | ||
| Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). | Q40613157 | ||
| Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study | Q42972380 | ||
| Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study | Q43264239 | ||
| A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer | Q44177869 | ||
| Surrogate endpoints: wishful thinking or reality? | Q44835530 | ||
| Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancer | Q45130075 | ||
| Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study | Q45154773 | ||
| Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study | Q45230546 | ||
| Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. | Q46638033 | ||
| Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. | Q46658481 | ||
| Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie | Q46694609 | ||
| Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer | Q46847510 | ||
| The validation of surrogate endpoints in meta-analyses of randomized experiments | Q47671365 | ||
| Bootstrap Methods: Another Look at the Jackknife | Q55950786 | ||
| Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis | Q56588945 | ||
| CONSORT for reporting randomised trials in journal and conference abstracts | Q56880300 | ||
| Surrogate Endpoints And FDA’s Accelerated Approval Process | Q56908800 | ||
| A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer | Q70753009 | ||
| Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group | Q72256279 | ||
| 5-fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma | Q72805222 | ||
| A phase III randomized study comparing doxifluridine and 5-fluorouracil as supportive chemotherapy in advanced and recurrent gastric cancer | Q73681739 | ||
| Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the | Q74000577 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1224-1231 | |
| P577 | publication date | 2011-02-25 | |
| P1433 | published in | Investigational New Drugs | Q2312231 |
| P1476 | title | Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials | |
| P478 | volume | 30 |
| Q39067386 | Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review |
| Q89485600 | CHALLENGES AND METHODOLOGIES IN USING PROGRESSION FREE SURVIVAL AS A SURROGATE FOR OVERALL SURVIVAL IN ONCOLOGY |
| Q43518078 | Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer |
| Q87211498 | PFS as a surrogate for overall survival in metastatic melanoma |
| Q43454040 | Perioperative DCF chemotherapy protocol for patients with gastroesophageal adenocarcinoma: correlation between response to treatment and outcome |
| Q43870660 | Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy |
| Q35541950 | Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer |
| Q37917630 | Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer |
| Q36349459 | Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology |
| Q98181145 | Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry |
| Q47178340 | Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy |
| Q54542682 | Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials. |
| Q33710118 | Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients |
| Q30538040 | Time-dependent endpoints as predictors of overall survival in multiple myeloma |
| Q38830206 | Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma. |
| Q38259501 | Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers. |
Search more.